Optimizing Patient Outcomes in the Era of PCSK9 Inhibitor Therapeutics
WebcastFaculty
OVERVIEW
Optimizing Patient Outcomes in the Era of PCSK9 Inhibitor Therapeutics is organized by Academic CME and will be held during Jun 29, 2017 - Jun 28, 2018.
The target audience for this medical event is Cardiologists, lipidologists, primary care, nurse practitioners, nurses and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Course Description :
This activity will focus on the most current clinical trial data for optimizing patient outcomes in the era of PCSK9 inhibitor therapeutics presented as an Industry-Supported Symposium at the National Lipid Association 2017 Scientific Sessions. Expert faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide vital information for lipidologsts to improve healthcare outcomes in their patients with statin intolerance, familial hypercholesterolemia and dyslipidemia.
Conference Objectives are :
• Review advances in LDL-C science and the role of LDL-C in CVD prevention
• Understand the current ACC/AHA/ESC/NLA guidelines for the management of patients with dyslipidemia.
• Analyze extended CVD Outcomes clinical trial data for PCSK9 inhibitor therapeutics.
• Apply newer scientific knowledge and data into personalized treatment plans for the healthcare team to manage patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.
The target audience for this medical event is Cardiologists, lipidologists, primary care, nurse practitioners, nurses and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia. This CME Conference has been approved for a maximum of 2.00 AMA PRA Category 1 Credits.
Course Description :
This activity will focus on the most current clinical trial data for optimizing patient outcomes in the era of PCSK9 inhibitor therapeutics presented as an Industry-Supported Symposium at the National Lipid Association 2017 Scientific Sessions. Expert faculty will utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide vital information for lipidologsts to improve healthcare outcomes in their patients with statin intolerance, familial hypercholesterolemia and dyslipidemia.
Conference Objectives are :
• Review advances in LDL-C science and the role of LDL-C in CVD prevention
• Understand the current ACC/AHA/ESC/NLA guidelines for the management of patients with dyslipidemia.
• Analyze extended CVD Outcomes clinical trial data for PCSK9 inhibitor therapeutics.
• Apply newer scientific knowledge and data into personalized treatment plans for the healthcare team to manage patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.
SPECIALITIES
CardiologyRELATED ONLINE COURSES
Quick Links